Liraglutide vs Tesofensine
A side-by-side research comparison of Liraglutide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Liraglutide | Tesofensine |
|---|---|---|
| Full name | Liraglutide (GLP-1 Receptor Agonist / Saxenda) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Binds and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 3,751 Da | 329.4 Da |
| Half-life | 13 hours | 8-10 days |
| Bioavailability | ~55% (subcutaneous) | High (oral ~93%) |
| Typical dose | 0.6-3.0 mg | 0.25-0.5 mg |
| Frequency | Once daily | Once daily |
| Route | Subcutaneous | Oral |
Liraglutide reported benefits
- Proven weight loss (5-10%)
- Long safety track record
- Cardiovascular benefit
- Improved glycemic control
- Reduced food intake
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.